Terms: = Liver cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
122 results:
1. Updates in the Management of Uveal Melanoma.
Barbi M; Carvajal RD; Devoe CE
Cancer J; 2024 Mar-Apr 01; 30(2):92-101. PubMed ID: 38527262
[TBL] [Abstract] [Full Text] [Related]
2. [Analysis and prediction of burden of viral hepatitis C-associated diseases in China from 1990 to 2044].
Zhou M; Yao L; Wu Y; Lin S; Huang J
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2023 Dec; 35(5):476-485. PubMed ID: 38148536
[TBL] [Abstract] [Full Text] [Related]
3. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract] [Full Text] [Related]
4. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
[TBL] [Abstract] [Full Text] [Related]
5. Contribution of an Asian-prevalent HLA haplotype to the risk of HBV-related hepatocellular carcinoma.
Kawamura A; Matsuda K; Murakami Y; Saruta M; Kohno T; Shiraishi K
Sci Rep; 2023 Aug; 13(1):12944. PubMed ID: 37558689
[TBL] [Abstract] [Full Text] [Related]
6. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract] [Full Text] [Related]
7. Novel
Khor SS; Ueno K; Nishida N; Kawashima M; Kawai Y; Aiba Y; Hitomi Y; Nagasaki M; Nakamura M; Tokunaga K
Front Immunol; 2023; 14():1151502. PubMed ID: 37325616
[TBL] [Abstract] [Full Text] [Related]
8. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract] [Full Text] [Related]
9. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract] [Full Text] [Related]
10. Prediction Model with
Nishida N; Ohashi J; Suda G; Chiyoda T; Tamaki N; Tomiyama T; Ogasawara S; Sugiyama M; Kawai Y; Khor SS; Nagasaki M; Fujimoto A; Tsuchiura T; Ishikawa M; Matsuda K; Yano H; Yoshizumi T; Izumi N; Hasegawa K; Sakamoto N; Mizokami M; Tokunaga K
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902191
[TBL] [Abstract] [Full Text] [Related]
11. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Garcia-Recio S; Hinoue T; Wheeler GL; Kelly BJ; Garrido-Castro AC; Pascual T; De Cubas AA; Xia Y; Felsheim BM; McClure MB; Rajkovic A; Karaesmen E; Smith MA; Fan C; Ericsson PIG; Sanders ME; Creighton CJ; Bowen J; Leraas K; Burns RT; Coppens S; Wheless A; Rezk S; Garrett AL; Parker JS; Foy KK; Shen H; Park BH; Krop I; Anders C; Gastier-Foster J; Rimawi MF; Nanda R; Lin NU; Isaacs C; Marcom PK; Storniolo AM; Couch FJ; Chandran U; Davis M; Silverstein J; Ropelewski A; Liu MC; Hilsenbeck SG; Norton L; Richardson AL; Symmans WF; Wolff AC; Davidson NE; Carey LA; Lee AV; Balko JM; Hoadley KA; Laird PW; Mardis ER; King TA; ; Perou CM
Nat Cancer; 2023 Jan; 4(1):128-147. PubMed ID: 36585450
[TBL] [Abstract] [Full Text] [Related]
12. PGG.MHC: toward understanding the diversity of major histocompatibility complexes in human populations.
Zhao X; Ma S; Wang B; Jiang X; ; Xu S
Nucleic Acids Res; 2023 Jan; 51(D1):D1102-D1108. PubMed ID: 36321663
[TBL] [Abstract] [Full Text] [Related]
13. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract] [Full Text] [Related]
14. [Effect evaluation of the primary screening strategy for liver cancer in rural areas of China].
Cao MM; Li H; Zha ZQ; Zhou JY; Luo PF; Gong JY; Ma HM; Sun XB; Chen WQ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):990-996. PubMed ID: 36164703
[No Abstract] [Full Text] [Related]
15. Tebentafusp for the treatment of hla-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract] [Full Text] [Related]
16. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.
Liu C; Liu H; Dasgupta M; Hellman LM; Zhang X; Qu K; Xue H; Wang Y; Fan F; Chang Q; Yu D; Ge L; Zhang Y; Cui Z; Zhang P; Heller B; Zhang H; Shi B; Baker BM; Liu C
Sci Rep; 2022 Jul; 12(1):12068. PubMed ID: 35840635
[TBL] [Abstract] [Full Text] [Related]
17. The Use of Molecular Dynamics Simulation Method to Quantitatively Evaluate the Affinity between HBV Antigen T Cell Epitope Peptides and hla-a Molecules.
Mei X; Li X; Zhao C; Liu A; Ding Y; Shen C; Li J
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563019
[TBL] [Abstract] [Full Text] [Related]
18. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D; Wells A; Clark AM
Sci Rep; 2022 Apr; 12(1):6657. PubMed ID: 35459800
[TBL] [Abstract] [Full Text] [Related]
19. Phase I/II Multicenter Trial of a Novel Therapeutic cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW; Gori S; Izzo F; Mayer-Mokler A; Ascierto PA; Königsrainer A; Ma YT; Sangro B; Francque S; Vonghia L; Inno A; Avallone A; Ludwig J; Alcoba DD; Flohr C; Aslan K; Mendrzyk R; Schuster H; Borrelli M; Valmori D; Chaumette T; Heidenreich R; Gouttefangeas C; Forlani G; Tagliamonte M; Fusco C; Penta R; Iñarrairaegui M; Gnad-Vogt U; Reinhardt C; Weinschenk T; Accolla RS; Singh-Jasuja H; Rammensee HG; Buonaguro L
Clin Cancer Res; 2022 Jun; 28(12):2555-2566. PubMed ID: 35421231
[TBL] [Abstract] [Full Text] [Related]
20. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
[Next]
